目的 探討腎復(fù)康片聯(lián)合氯沙坦鉀片治療慢性腎小球腎炎的臨床療效。方法 選取2020年12月—2022年6月在商丘市第一人民醫(yī)院的收治的122例慢性腎小球腎炎患者，根據(jù)隨機數(shù)字表法將全部患者分為對照組和治療組，每組各61例。對照組口服氯沙坦鉀片，1片/次，1次/d。治療組在對照組治療的基礎(chǔ)上口服腎復(fù)康片，6片/次，3次/d。兩組持續(xù)治療12周。觀察兩組的臨床療效，比較兩組血尿、蛋白尿的轉(zhuǎn)陰時間以及血清血肌酐（Scr）、尿白蛋白排泄率（UAER）、尿24 h尿蛋白定量（24 h Upro）、尿紅細胞、尿中性粒細胞明膠酶相關(guān)脂質(zhì)運載蛋白（NGAL）、尿激酶型纖溶酶原激活物受體（uPAR）、β₂-微球蛋白（β₂-MG）、白細胞誘素-1（Lkn-1）、白細胞介素-13（IL-13）、基質(zhì)金屬蛋白酶-9（MMP-9）水平。結(jié)果 治療后，治療組的總有效率為95.08%，明顯高于對照組的83.61%（P＜0.05）。治療后，治療組血尿、蛋白尿轉(zhuǎn)陰時間均明顯短于對照組，差異有統(tǒng)計學(xué)意義（P＜0.05）。治療后，兩組血清Scr、UAER和尿24 h Upro、尿紅細胞明顯低于治療前（P＜0.05），且治療組血清Scr、UAER和尿24 h Upro、尿紅細胞低于對照組，差異有統(tǒng)計學(xué)意義（P＜0.05）。治療后，兩組的NGAL、uPAR、β₂-MG水平低于治療前（P＜0.05），且治療組的NGAL、uPAR、β₂-MG低于對照組（P＜0.05）。治療后，兩組血清Lkn-1、IL-13、MMP-9水平低于對照組（P＜0.05）；治療組的血清Lkn-1、IL-13、MMP-9水平低于對照組（P＜0.05）。結(jié)論 腎復(fù)康片聯(lián)合治療氯沙坦鉀片治療慢性腎小球腎炎的療效確切，能減輕臨床癥狀、炎癥反應(yīng)和腎功能損傷，安全性良好。

Objective To investigate the clinical effect of Shenfukang Tablets combined with Losartan Potassium Tablets in treatment of chronic glomerulonephritis. Methods Patients (122 cases) with chronic glomerulonephritis in the First People’s Hospital of Shangqiu from December 2020 to June 2022 were divided into control and treatment groups according to the random number table method, and each group had 61 cases. Patients in the control group were po administered with Losartan Potassium Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Shenfukang Tablet on the basis of the control group, 6 tablets/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and the conversion time of hematuria and proteinuria, the levels of Scr, UAER, 24 h Upro, urinary erythrocytes, NGAL, uPAR, and β₂-MG, Lkn-1, IL-13, and MMP-9 in two groups were compared. Results After treatment, the total effective rate of the treatment group was 95.08%, which was significantly higher than 83.61% of the control group (P < 0.05). After treatment, the time of turning negative of hematuria and albuminuria in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the serum Scr, UAER, urine 24h Upro, and urine red blood cells in two groups were significantly decreased(P < 0.05), and the serum Scr, UAER, urine 24h Upro, and urine red blood cells in the treatment group were lower than those in the control group, with statistically significant difference (P < 0.05). After treatment, the levels of NGAL, uPAR, and β₂-MG was lower than that before treatment (P < 0.05), and the levels of NGAL, uPAR, and β₂-MG was lower than that in the control group (P < 0.05). Conclusion Shenfukang Tablets combined with Losartan Potassium Tablets has definite curative effect in treatment of chronic glomerulonephritis, can alleviate clinical symptoms, inflammatory reaction, and renal damage with good safety.

R983

河南省醫(yī)學(xué)科技攻關(guān)計劃聯(lián)合共建項目（LHGJ20191505）